|Bid||25.99 x 2200|
|Ask||26.07 x 1800|
|Day's Range||25.00 - 26.09|
|52 Week Range||18.12 - 57.21|
|Beta (5Y Monthly)||1.02|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug. 03, 2021 - Aug. 09, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||36.29|
New York, New York--(Newsfile Corp. - June 12, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN) and certain of its officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 21-cv-03212, is on behalf of a class consisting of all persons and entities other than Defendants who purchased ...
NEW YORK, NY / ACCESSWIRE / June 11, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit.
Los Angeles, California--(Newsfile Corp. - June 11, 2021) - The Schall Law Firm announced today that they have filed a securities class action lawsuit on behalf of plaintiff Thomas Leonard against FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN) and certain of its officers, which expands the class period. The class action is on behalf of a class consisting of investors who purchased or otherwise acquired FibroGen securities between October 18, 2017 and April ...